← All trials
NCT05245292
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 1, 2025
- First posted
- Feb 17, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rockefeller UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of PennsylvaniaCollaborator
- Rockefeller UniversityOverall official - principal investigator
- Cornell UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.